Pharmatest Services
Pharmatest Services is a Finnish preclinical CRO founded in 1998 that provides clinically predictive in vitro, in vivo, and ex vivo efficacy testing in oncology and musculoskeletal diseases for biopharmaceutical and biotechnology clients worldwide.
- Company typePrivate
- Founded1998
- HeadquartersTurku, Finland
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Pharmatest Services does
Pharmatest Services Ltd (legal entity Pharmatest Services Oy) is a Turku, Finland-based contract research organization founded in 1998 that provides clinically predictive preclinical efficacy services for biopharmaceutical drug developers. Its work is organized around two pillars — cancer models and musculoskeletal disease models — and spans in vitro assays, in vivo efficacy studies, and ex vivo bone analysis (histomorphometry, micro-CT imaging, biomarkers). Differentiated capabilities include orthotopic and bone metastasis models, humanized mouse models for immuno-oncology, osteoarthritis and rare bone disease models (including osteogenesis imperfecta), and licensed handling of alpha-emitting radiopharmaceuticals such as Ra-223, Ra-224, and Th-227.
The company operates state-of-the-art laboratories in Turku and runs regional sales offices in Boxborough, MA and San Diego, CA, plus a Guangzhou, China agency office, selling fee-for-service study contracts to enterprise pharmaceutical and biotechnology customers. Revenue is generated primarily through project-based preclinical efficacy contracts; pricing is quote-based and not publicly disclosed. The customer roster includes Bayer AG, Exelixis, Orion Oyj, Boehringer Ingelheim, Astellas, Zealand Pharma, Taconic Biosciences, Pfenex, Transgene, and Aurexel Life Sciences, with several relationships spanning more than a decade.
Pharmatest monetizes a portfolio of specialized biological assets — including the proprietary KS483 cell line and disease-specific animal models — and supports its offering with ISO 9001:2015 quality certification, EcoVadis Bronze Medal recognition, French CIR approval for 2024–2028, and an active scientific publication and conference presence (AACR, ASBMR, OARSI, ECTS, BIO). Go-to-market is sales-led via direct enterprise engagement, scientific publications, and major industry conferences; the firm holds no disclosed patents, no public APIs, and no AI/ML capabilities in the input data.
Pharmatest Services firmographics
Firmographics- Name
- Pharmatest Services
- Legal name
- Pharmatest Services Oy
- Website
- https://pharmatest.com
- Company type
- Private
- Founded year
- 1998
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Pharmatest Services is a Finnish preclinical CRO founded in 1998 that provides clinically predictive in vitro, in vivo, and ex vivo efficacy testing in oncology and musculoskeletal diseases for biopharmaceutical and biotechnology clients worldwide.
- Ownership category
- akta.pro rank
Pharmatest Services industry classification
Industry- Product category
- Preclinical Contract Research Services
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)
- akta.pro secondary industry
- Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD)
Keywords
Where Pharmatest Services is headquartered
LocationHeadquarters
- HQ city
- Turku
- HQ country
- Finland
- HQ region
- Europe
Offices4 records
Markets served
Pharmatest Services business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Preclinical Contract Research Services: Pharmatest generates revenue by providing fee-for-service preclinical efficacy testing contracts to biopharmaceutical companies. Services include in vitro assays, in vivo efficacy models, and ex vivo bone analysis. Projects are typically custom-designed studies contracted through quotes. The company has thousands of compounds tested across their 25+ year history.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Pharmatest Services product offering
Product offeringCore offering
Pharmatest Services is a preclinical contract research organization (CRO) providing clinically predictive in vitro, in vivo, and ex vivo efficacy testing services for biopharmaceutical clients. Its offerings are organized around two core domains — cancer models (xenograft, syngeneic, immuno-oncology, orthotopic, and bone metastasis) and musculoskeletal disease models (osteoporosis, osteoarthritis, rare bone diseases) — supplemented by bone analysis, biomarker measurement, radiopharmaceutical testing, hormonal action bioassays, pain assessment, and biostatistics. Services are sold on a fee-for-service, quote-based engagement model with no resellers or distributors.
Product overview
Pharmatest Services is a full-service preclinical CRO (Contract Research Organization) providing clinically predictive preclinical models for oncology and musculoskeletal disease research. The company offers a comprehensive portfolio organized around two core service areas: Cancer Models (covering xenograft, syngeneic, and immuno-oncology models with special expertise in bone metastasis) and Musculoskeletal Disease Models (including osteoporosis, osteoarthritis, and rare bone disease models). Supporting services include in vitro assays (osteoblasts, osteoclasts, chondrogenic differentiation), bone analysis (histomorphometry, micro-CT imaging), biomarker measurement, radiopharmaceuticals testing, pain assessment, and statistical services. The company operates state-of-the-art laboratories in Finland with a US office in Massachusetts, serving pharmaceutical and biotech companies worldwide.
Differentiator
Problem solved
Functional benefit
Products and services
- Cancer Models Comprehensive portfolio of preclinical oncology efficacy models for biopharmaceutical clients, including xenograft, syngeneic, immuno-oncology, orthotopic, and bone metastasis models. For oncology drug developers evaluating targeted therapies, immunotherapies, radiopharmaceuticals, and combination treatments.
- Musculoskeletal Disease Models
Quantifiable outcome
- Clinically predictive models designed to decrease high failure rates in clinical trials
- +1 more outcomes
Companies that use Pharmatest Services
Customer profileNamed customers11 records
Segments3 records
Ideal customer profiles3 records
Pharmatest Services technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
Pharmatest Services partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered core, major and minor.
- NK-ENGAGE Consortium (EUROSTARS)coreNordic consortium funded by EUROSTARS for NK cell engager therapies for multiple myeloma treatment. Pharmatest Services is a partner providing preclinical evaluation of novel synthetic polypeptides for NK cell-mediated immunotherapy.
- Bayer AGcoreLong-standing collaboration on radium-223 (Xofigo) combination therapies for bone metastasis; PSMA-targeted thorium-227 conjugates for prostate cancer; multiple joint publications and poster presentations at AACR. Partnership involves preclinical efficacy testing and model development for targeted alpha therapies.
- Aurexel Life Sciences Ltd.coreCollaboration on preclinical evaluation of radiopharmaceutical combinations for bone metastases; co-authorship on multiple publications including radium-223 combination studies with Bayer AG. Provides scientific consultation and preclinical research support.
- Taconic BiosciencesmajorCollaboration on humanized mouse models for immuno-oncology research; establishment of primary tumor models of TNBC and ER+/HER2- breast cancer in humanized mice; joint presentations at AACR and other conferences.
- Boehringer Ingelheim Pharmaceuticals, Inc.majorCollaboration on bone turnover marker assessment in marmoset serum for preclinical studies; joint poster presentation at ASBMR 2022.
- Astellas Innovation Management LLCmajorCollaboration on evaluation of knee pain and degenerative changes in rat model of post-traumatic knee osteoarthritis; joint poster presentation at ASBMR 2022.
- Exelixis Inc.majorLong-term collaboration since 2011 on preclinical oncology studies; praised for excellent data quality, detailed reports, and professional staff.
- Orion CorporationmajorMore than 10 years of collaboration on preclinical skeletal disease models including SARM (Selective Androgen Receptor Modulator) programs; joint publications on osteoporosis research.
- Pfenex Inc.majorCollaboration on PF708, a therapeutic equivalent and biosimilar candidate to Forteo (teriparatide), demonstrating nonclinical efficacy equivalence in ovariectomized rat model.
- Zealand Pharma A/SmajorCollaboration on novel cyclic PTH(1-17) analogs and other osteoporosis drug candidates; joint ASBMR presentations on bone turnover markers.
- TransgenemajorCollaboration since 2009 for preclinical evaluation of TG's monoclonal platform in different skeletal diseases; joint presentations at conferences.
- Virobay Inc.majorCollaboration on in vitro and in vivo model analysis of cathepsin inhibitor drug candidates for cancer and bone metastasis.
- Women's Health Hub FinlandminorPharmatest is part of WHHF initiative driving innovation in female-focused healthcare; supports women's health research ecosystem in Finland.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
Pharmatest Services competitors and assessment
Company assessmentDirect peers
- Inotiv: Inotiv (formed via Envigo merger) is a US preclinical CRO offering toxicology, disease models, and research services to biopharma. Direct overlap on in vivo efficacy and safety assessment for small-molecule and biologic pipelines at comparable scale.
- Porsolt: Porsolt is a French preclinical CRO providing pharmacology and safety pharmacology services across CNS, metabolic, and musculoskeletal indications. Comparable European specialist CRO with similar headcount and biopharma customer base.
- Oncodesign: Oncodesign is a French preclinical CRO specialising in oncology and immunology drug discovery with proprietary in vivo and in vitro efficacy platforms. Comparable in size (~150 staff) and therapeutic focus (solid tumour + immuno-oncology), making it a strong European specialist comparable.
- Shanghai Medicilon: Medicilon is a China-based preclinical CRO offering in vivo and in vitro pharmacology, toxicology, and oncology efficacy services for global biopharma. Direct overlap on preclinical oncology and small-molecule efficacy testing services.
- Champions Oncology: Champions Oncology operates a proprietary patient-derived xenograft (PDX) and tumour bank platform used in preclinical oncology efficacy studies for biopharma sponsors. Direct overlap on oncology in vivo efficacy with a similarly specialised, model-centric value proposition.
- Crown Bioscience: Crown Bioscience is a global preclinical CRO specialising in oncology and immuno-oncology in vivo models (xenograft, syngeneic, humanized mouse), serving the same biopharma translational customers as Pharmatest. Direct overlap on oncology efficacy and humanized mouse platforms makes it the closest head-to-head comparable.
Broad incumbents
- Eurofins Scientific: Eurofins is a global testing services group whose BioPharma Product Testing arm includes preclinical and discovery services. Comparable at the broad-services level rather than the specialized bone-metastasis niche; relevant as a pricing/benchmark reference.
- Wuxi AppTec: Wuxi AppTec is a leading China-based global CRO/CDMO offering preclinical efficacy and safety services alongside clinical and manufacturing capabilities. Overlaps with Pharmatest on oncology preclinical work and is a credible Asia-headquartered competitor for global biopharma sponsors.
- Charles River Laboratories: Charles River is the largest publicly-traded preclinical CRO, offering discovery, safety assessment, and oncology model services globally. It competes with Pharmatest on oncology efficacy studies at the top end of the market but operates across a far broader service portfolio.
Others
- Taconic Biosciences: Taconic supplies genetically engineered and humanized mouse models used in preclinical research and is a named collaboration partner of Pharmatest for humanized mouse and immuno-oncology work. Not a direct CRO competitor but an ecosystem participant in the same humanized-mouse workflow.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Pharmatest Services social profiles
Digital presencePharmatest Services compliance and trust
Trust signalCompliance4 records
Pharmatest Services financial estimates
Financial estimateRevenue estimate
Valuation estimate
Pharmatest Services leadership team
Management profileNumber of profiles
Profiles7 records
Pharmatest Services funding detail
Funding detailFunding overview
Funding rounds3 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Pharmatest Services M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Pharmatest Services
What does Pharmatest Services do?
Pharmatest Services is a preclinical contract research organization (CRO) providing clinically predictive in vitro, in vivo, and ex vivo efficacy testing services for biopharmaceutical clients. Its offerings are organized around two core domains — cancer models (xenograft, syngeneic, immuno-oncology, orthotopic, and bone metastasis) and musculoskeletal disease models (osteoporosis, osteoarthritis, rare bone diseases) — supplemented by bone analysis, biomarker measurement, radiopharmaceutical testing, hormonal action bioassays, pain assessment, and biostatistics. Services are sold on a fee-for-service, quote-based engagement model with no resellers or distributors.
Is Pharmatest Services a public or private company?
Pharmatest Services is a private company. It is classified as venture growth investor backed and is currently operating.
When was Pharmatest Services founded?
Pharmatest Services was founded in 1998. It employs 11 to 50 people.
Where is Pharmatest Services based?
Pharmatest Services is headquartered in Turku, Finland, in the Europe region.
How does Pharmatest Services make money?
One revenue line is on record: preclinical Contract Research Services.
Who are Pharmatest Services's main competitors?
Direct peers on record are Inotiv, Porsolt, Oncodesign, Shanghai Medicilon, Champions Oncology and Crown Bioscience. Broad incumbents are Eurofins Scientific, Wuxi AppTec and Charles River Laboratories. Taconic Biosciences is listed as an others.
Does Pharmatest Services have an API?
No public API is recorded for Pharmatest Services.
What industry is Pharmatest Services in?
Pharmatest Services's product category is Preclinical Contract Research Services. Its primary akta.pro industry code is HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease), with a secondary code of HLAGAAAD, Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity). Its SIC code is 8731.